Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Farmers Insurance
Fuji
Fish and Richardson
Cerilliant
Julphar
McKesson
Medtronic
Express Scripts
Accenture

Generated: October 23, 2017

DrugPatentWatch Database Preview

ACULAR LS Drug Profile

« Back to Dashboard

Which patents cover Acular Ls, and when can generic versions of Acular Ls launch?

Acular Ls is a drug marketed by Allergan and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has four patent family members in three countries and six supplementary protection certificates in six countries.

The generic ingredient in ACULAR LS is ketorolac tromethamine. There are eighteen drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the ketorolac tromethamine profile page.

Summary for Tradename: ACULAR LS

US Patents:8
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list44
Clinical Trials: see list16
Patent Applications: see list4,781
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ACULAR LS at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
ACULAR LS
ketorolac tromethamine
SOLUTION/DROPS;OPHTHALMIC021528-001May 30, 2003ATRXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
ACULAR LS
ketorolac tromethamine
SOLUTION/DROPS;OPHTHALMIC021528-001May 30, 2003ATRXYesYes► Subscribe► SubscribeY► Subscribe
Allergan
ACULAR LS
ketorolac tromethamine
SOLUTION/DROPS;OPHTHALMIC021528-001May 30, 2003ATRXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan
ACULAR LS
ketorolac tromethamine
SOLUTION/DROPS;OPHTHALMIC021528-001May 30, 2003ATRXYesYes► Subscribe► SubscribeY► Subscribe
Allergan
ACULAR LS
ketorolac tromethamine
SOLUTION/DROPS;OPHTHALMIC021528-001May 30, 2003ATRXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
ACULAR LS
ketorolac tromethamine
SOLUTION/DROPS;OPHTHALMIC021528-001May 30, 2003ATRXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
ACULAR LS
ketorolac tromethamine
SOLUTION/DROPS;OPHTHALMIC021528-001May 30, 2003ATRXYesYes► Subscribe► SubscribeY► Subscribe
Allergan
ACULAR LS
ketorolac tromethamine
SOLUTION/DROPS;OPHTHALMIC021528-001May 30, 2003ATRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ACULAR LS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan
ACULAR LS
ketorolac tromethamine
SOLUTION/DROPS;OPHTHALMIC021528-001May 30, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ACULAR LS

Drugname Dosage Strength RLD Submissiondate
ketorolac tromethamineOphthalmic Solution0.40%Acular LS1/28/2005

International Patent Family for Tradename: ACULAR LS

Country Document Number Estimated Expiration
Canada2967362► Subscribe
World Intellectual Property Organization (WIPO)2016077726► Subscribe
European Patent Office3217937► Subscribe
Canada2468664► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ACULAR LS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0090France► SubscribePRODUCT NAME: SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1018 20150728
2015000111Germany► SubscribePRODUCT NAME: OKULARE IRRIGATIONSLOESUNG, WELCHE PHENYLEPHRIN ODER DESSEN PHARMAZEUTISCH WIRKSAMES SALZ UND KETOROLAC ODER DESSEN PHARMAZEUTISCH WIRKSAMES SALZ UMFASST; REGISTRATION NO/DATE: EU/1/15/1018 20150728
0784Netherlands► SubscribePRODUCT NAME: EEN OCULAIRE OPLOSSING WELKE FENYLEFRINE BEVAT, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN, ALSMEDE KETOROLAC, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/15/1018 20150730
923Luxembourg► SubscribePRODUCT NAME: UNE SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION: 20150730
/2015Austria► SubscribePRODUCT NAME: PHENYLEPHRIN, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, UND KETOROLAC, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1018 (MITTEILUNG) 20150730
2015 00072Denmark► SubscribePRODUCT NAME: OKULAER SKYLLEVAESKE OMFATTENDE PHENYLEPHRIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER HYDROCHLORID OG KETOROLAC ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER KETOROLACTROMETAMOL; REG. NO/DATE: EU/1/15/1018 20150730
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
US Department of Justice
Accenture
Cerilliant
Queensland Health
Daiichi Sankyo
AstraZeneca
Julphar
Cantor Fitzgerald
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot